Mandate

Vinge advises Tigran Technologies in its new issue

April 29, 2009

Vinge is advising Tigran Technologies AB (publ), listed on AktieTorget, in its new issue of preference shares and warrants subject to pre-emption rights for the existing shareholders.

As a result of the new issue, which is underwritten in its entirety by the principal shareholders and an external syndicate, Tigran will initially receive SEK 20 million as well as up to an additional SEK 30 million in conjunction with full exercise of the warrants.

Vinge’s team was led by Jesper Ottergren who was assisted by, among others, associates Christian Lindhé and Ida Christensson.

Related

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024

Vinge advises Triton in connection with the divestment of Norstat to Nalka Invest

Vinge advises Triton Smaller Mid-Cap Fund I (“Triton”) in connection with the divestment of Norstat, a leading data collector for market research, to Nalka Invest.
April 12, 2024